Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A.

N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965.

2.

Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.

Minich SS.

Ann Pharmacother. 2012 Mar;46(3):377-83. doi: 10.1345/aph.1Q680. Epub 2012 Mar 6. Review.

PMID:
22395252
3.

Brentuximab vedotin for the treatment of CD30+ lymphomas.

Foyil KV, Bartlett NL.

Immunotherapy. 2011 Apr;3(4):475-85. doi: 10.2217/imt.11.15. Review.

PMID:
21463188
4.

[Brentuximab vedotin: new treatment for CD30+ lymphomas].

Terriou L, Bonnet S, Debarri H, Demarquette H, Morschhauser F.

Bull Cancer. 2013 Jul-Aug;100(7-8):775-9. doi: 10.1684/bdc.2013.1778. Review. French.

PMID:
23831822
5.

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.

Gualberto A.

Expert Opin Investig Drugs. 2012 Feb;21(2):205-16. doi: 10.1517/13543784.2011.641532. Epub 2011 Nov 30. Review.

PMID:
22127011
6.

Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.

Ansell SM.

Expert Opin Investig Drugs. 2011 Jan;20(1):99-105. doi: 10.1517/13543784.2011.542147. Epub 2010 Dec 2. Review.

PMID:
21121873
7.

Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.

Bradley AM, Devine M, DeRemer D.

Am J Health Syst Pharm. 2013 Apr 1;70(7):589-97. doi: 10.2146/ajhp110608. Review.

PMID:
23515511
8.

Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.

Chen R, Chen B.

Drug Des Devel Ther. 2015 Mar 23;9:1729-33. doi: 10.2147/DDDT.S82007. eCollection 2015. Review.

9.

Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.

Haddley K.

Drugs Today (Barc). 2012 Apr;48(4):259-70. doi: 10.1358/dot.2012.48.4.1788435. Review.

PMID:
22536568
10.

Role of CD30 targeting in malignant lymphoma.

Kumar A, Younes A.

Curr Treat Options Oncol. 2014 Jun;15(2):210-25. doi: 10.1007/s11864-014-0275-7. Review.

PMID:
24570331
11.

Brentuximab vedotin.

van de Donk NW, Dhimolea E.

MAbs. 2012 Jul-Aug;4(4):458-65. doi: 10.4161/mabs.20230. Epub 2012 Jul 1. Review.

12.

Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?

Goyal SD, Bartlett NL.

Curr Hematol Malig Rep. 2012 Sep;7(3):179-85. doi: 10.1007/s11899-012-0126-1. Review.

PMID:
22669711
13.

Brentuximab vedotin.

Deng C, Pan B, O'Connor OA.

Clin Cancer Res. 2013 Jan 1;19(1):22-7. doi: 10.1158/1078-0432.CCR-12-0290. Epub 2012 Nov 15. Review.

14.

CD30 as a therapeutic target for lymphoma.

Schirrmann T, Steinwand M, Wezler X, Ten Haaf A, Tur MK, Barth S.

BioDrugs. 2014 Apr;28(2):181-209. doi: 10.1007/s40259-013-0068-8. Review.

PMID:
24043362
15.

The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.

Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V.

Curr Med Res Opin. 2015 Mar;31(3):537-45. doi: 10.1185/03007995.2015.1008131. Epub 2015 Feb 9. Review.

PMID:
25598441
16.
17.

Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma.

Lai CM, Horowitz S.

Expert Rev Hematol. 2013 Aug;6(4):361-73. doi: 10.1586/17474086.2013.814434. Review.

PMID:
23991923
18.

Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.

Mei M, Thomas S, Chen R.

BioDrugs. 2014 Jun;28(3):245-51. doi: 10.1007/s40259-013-0077-7. Review.

19.

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.

Siddiqi T, Thomas SH, Chen R.

Pharmgenomics Pers Med. 2014 Feb 20;7:79-85. doi: 10.2147/PGPM.S57700. eCollection 2014. Review.

20.

Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.

Zinzani PL, Sasse S, Radford J, Shonukan O, Bonthapally V.

Crit Rev Oncol Hematol. 2015 Sep;95(3):359-69. doi: 10.1016/j.critrevonc.2015.03.011. Epub 2015 Apr 27. Review.

PMID:
25964164

Supplemental Content

Support Center